SPRINGFIELD, N.J.,
May 21,
2024 /PRNewswire/ -- Evergreen Theragnostics,
Inc., a clinical-stage radiopharmaceutical company, today
announced that they have entered into a collaboration and
licensing-agreement with the Medical University of Innsbruck (MUI),
a leading European research institution to advance the development
of novel radiopharmaceuticals. The agreement covers the clinical
development of EVG321, a novel radioligand therapy (RLT) for small
cell lung cancer (SCLC), targeting the cholecystokinin 2 receptor
(CCK2R).
RLTs have surged into the clinic and represent a rapidly
expanding market. By combining the power of medical isotopes and
the precision of targeted therapeutics, these types of medicines
allow for cell-specific ablation of a tumor target, thereby
localizing ionizing radiation to diseased tissues. CCK2R has been
shown to be highly expressed in SCLC, and has the potential to
facilitate robust, tumor-specific delivery.
"We are very pleased to announce this new collaboration with
the Medical University of Innsbruck," commented James Cook, CEO of Evergreen Theragnostics.
"For several years, the research groups of Univ. Prof. Dr. Irene
Virgolini and Priv. Doz. Dr. Elisabeth von
Guggenberg in Innsbruck have established themselves as key
innovators in the RLT-field, and we are excited to be working with
them on one of their lead programs – this was an easy choice to
make." He added: "Especially in the realm of small cell lung
cancer, novel therapies are urgently needed, and we are confident
that EVG321 has the potential to
significantly improve outcomes for cancer patients in
this indication."
Univ. Prof. Dr. Irene Virgolini, Medical University of
Innsbruck, said: "Evergreen Discovery is a pioneer in the field
of radiopharmaceuticals, and their team is looking back on an
impressive record in bringing novel medicines to patients. We are
delighted to be collaborating with them. In conjunction with their
subject matter expertise and proven ability to translate new
radioligand therapies, it is their exceptional sense of urgency to
bring novel drugs to patients in need, making them such valuable
partners for us."
Over the next months, Evergreen intends to begin registration
enabling therapeutic and diagnostic clinical trials for
Lutetium-177 (177Lu) EVG321 and Gallium-68
(68Ga) EVG321. If successful, EVG321 could offer new
hope to patients with small cell lung cancer.
About Evergreen Theragnostics, Inc.
Evergreen Theragnostics is focused on improving the available
options for cancer patients using radiopharmaceuticals. The company
is engaged in Contract Development and Manufacturing (CDMO)
services as well as drug discovery and commercialization of
proprietary products. Evergreen is headquartered in Springfield, NJ in a state-of-the-art GMP
radiopharmaceutical facility. The company was founded in 2019 by a
team that brings a strong track record in theragnostic
radiopharmaceutical manufacturing, research, and clinical
development.
For more information, please visit www.evergreentgn.com.
About Medical University of Innsbruck
Medical University of Innsbruck has approximately 2,200
employees and around 3,400 students and, together with the
University of Innsbruck, is the largest educational and research
institution in western Austria and
the regional university for Tyrol, Vorarlberg, South Tyrol and Liechtenstein. Medical University of Innsbruck
is involved in numerous international educational and research
programmes and networks. The research focuses on the areas
Oncology, Neuroscience, Genetics, Epigenetics and Genomics as well
as Infectious Diseases, Immunology & Organ and Tissue Repair.
In addition to scientific research, Medical University of Innsbruck
is also nationally and internationally very successful in the
highly competitive field of research funding.
For more information on Medical University of Innsbruck, please
visit www.i-med.ac.at
For further information, please contact:
James Cook
President & CEO
james.cook@evergreentgn.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/evergreen-theragnostics-announces-licensing-of-evg321-from-medical-university-of-innsbruck-and-enters-clinical-development-of-radioligand-therapies-in-small-cell-lung-cancer-302151441.html
SOURCE Evergreen Theragnostics, Inc.